QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kitsGlobeNewsWire • 09/25/23
QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlookGlobeNewsWire • 08/08/23
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines' AYVAKIT® (avapritinib) in gastrointestinal stromal tumorsGlobeNewsWire • 08/07/23
QIAGEN expands range of digital PCR kits and services for the biopharma industryGlobeNewsWire • 07/18/23
FBI approves QIAGEN's NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)GlobeNewsWire • 06/20/23
QIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notesGlobeNewsWire • 06/16/23
QIAGEN's QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screeningGlobeNewsWire • 06/15/23
Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencingGlobeNewsWire • 06/13/23